Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT - PROGRESS UPDATE ON THE PLAN FOR INCREASE IN SHAREHOLDING BY A CONTROLLING SHAREHOLDER（H SHARES）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take

no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（集 團）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT

PROGRESS UPDATE ON THE PLAN FOR INCREASE IN SHAREHOLDING BY A

CONTROLLING SHAREHOLDER

This announcement is made on a voluntary basis by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company").

Reference is made to the announcement of the Company dated 1 December 2020 (the "Announcement")

in relation to, among others, the Shareholding Increase Plan of Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技（集團）有限公司) ("Fosun High Tech"), the controlling

shareholder of the Company. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Announcement.

PROGRESS UPDATE ON THE SHAREHOLDING INCREASE PLAN

1. During the period from 1 December 2020 to 21 January 2021, Fosun High Tech acquired through the Shanghai-Hong Kong Stock Connect of the Shanghai Stock Exchange an aggregate number of 18,030,500 H Shares (representing approximately 0.70% of the total issued shares of the Company as at 1 December 2020) for an aggregate amount of approximately RMB552.90 million pursuant to the Shareholding Increase Plan.
   Further, the Company was notified by Fosun High Tech that, as at 21 January 2021, Fosun High Tech has acquired an aggregate number of shares in the Company, pursuant to the Shareholding Increase Plan and the previous plan for shareholding increase, representing approximately 1.10% of the total number of shares in issue of the Company as at the date of this announcement since 1 March 2020 (the "Equity Change"), being the date on which the Securities Law of the People's Republic of China (as amended) ("Securities Law") came into force.
2. There is no violation of the Securities Law, Measures for the Administration of the Takeover of Listed Companies and relevant regulations and rules of the Shanghai Stock regarding the Equity Change.

1

3. The Company will continue to pay attention to the situation regarding the shareholding increase in the Company by Shareholding Increase Party/Parties and make timely disclosure of the relevant information pursuant to the relevant regulations under the Rules Governing the Listing of Stocks on Shanghai Stock Exchange, Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited, Measures for the Administration of the Takeover of Listed Companies and Guidelines for the Increase in Shareholdings by Shareholders of Listed Companies and Persons Acting in Concert with Such Shareholders of Shanghai Stock Exchange.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, PRC

22 January 2021

As at the date of this announcement, the executive Director of the Company is Mr. Wu Yifang; the non-

executive Directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive Directors of the

Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

2